Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China to Audit 77 Pharmas after Kangmei Reports $4.4 Billion Fraud

publication date: Jun 7, 2019

China announced plans to audit 77 major pharmaceutical companies over the next two months, including the China operations of three multinationals, Bristol-Myers Squibb, Sanofi and Lilly. The 77 companies were chosen randomly, not because China suspects any specific company of wrongdoing. The audits are a government response to a surprise announcement from Kangmei Pharma, a TCM company, that it had "overstated" its cash reserves by a jaw-dropping $4.4 billion. Apparently, Kangmei filed false invoices to inflate its sales and cash position. More details....

Stock Symbol: (NYSE: BMY) (NYSE: SNY) (NYSE: LLY) (SHA: 600518)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.